Weekly shot may boost growth in teens with dwarfism
NCT ID NCT06732895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a weekly injection called navepegritide in 24 teenagers (ages 12-18) with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over one year compared to a placebo. The treatment aims to manage the condition by improving height, but does not cure the underlying genetic cause.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGMontreal, H3T 1C5, Canada
-
Ascendis Investigational Site
RECRUITINGCopenhagen, 2100, Denmark
-
Ascendis Investigational Site
RECRUITINGParis, 75743, France
-
Ascendis Investigational Site
RECRUITINGDublin, D01 YC76, Ireland
-
Ascendis Investigational Site
RECRUITINGNorwich, NR4 7UY, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Weekly shot may boost growth in kids with dwarfism
- Experimental achondroplasia drug trial halted early
- No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
- New drug aims to boost height in kids with dwarfism
- New registry aims to unlock secrets of bone disorder
- New hope for kids with dwarfism: daily shot may boost growth